
Robert Sciscento, a senior scientist at Alcami Corporation, discusses scaling up oral peptide products and what the future looks like for GLP-1 drug delivery.
Combination Drugs - Adding Up the Opportunities in Solid Dosage
about 14 years ago
Integration of Less-Formal Risk Assessment Tools into Change Controlabout 14 years ago
Technical Forum: Disposable Chromatographyabout 14 years ago
Uniformity of Dosage Units Using Large Sample Sizesabout 14 years ago
A World without R&Dabout 14 years ago
Supplier Qualificationabout 14 years ago
Determining Potency of Preclinical Dose Formulationsabout 14 years ago
Report from India





